Bristol Myers Squibb And Exelixis Announce Topline Results From Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo In Combination With CABOMETYX In Previously Untreated Advanced Renal Cell Carcinoma; Study Met Primary Endpoint
Benzinga Newsdesk